clinical trial · NCT06336603
A Study Assessing the Efficacy of Combined Use of Clascoterone 1% Cream and Adapalene 0.3% for the Treatment of Acne
Acne VulgarisWinlevi (clascoterone) 1% & Adapalene 0.3% gel
brief summary
Winlevi is the first topical anti androgen and sebum inhibitor approved for acne vulgaris. There is no study assessing Winlevi in combination treatment for acne .Therefore this study assesses Winlevi with Adapalene 0.3% gel in combination to emulate real life practice.
started
Nov 15, 2023
primary completion
Oct 29, 2024
completion
Oct 29, 2024
last updated
Oct 9, 2025
official title
The Combination Use of Winlevi and Adapalene 0.3% Gel in Real Life Acne Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol